Is Tysabri a form of chemotherapy?
Tysabri is not chemotherapy, it is a targeted treatment that works by blocking the migration of lymphocytes (a type of immune cell) from the lymph nodes, across the epithelium, and into inflamed tissue. It binds to a receptor that is present on all leukocytes apart from neutrophils and prevents them from binding to their counter receptors. It may also act in several other ways to prevent the further recruitment and inflammatory activity of activated immune cells. Tysabri belongs to the class of medicines known as integrin receptor antagonists. It may also be called a selective immunosuppressant or a monoclonal antibody.
The way Tysabri works specifically in MS or Crohn's disease is not completely understood. In MS it may be due to a reduction of lymphocyte migration into brain tissue and a reduction in plaque formation. In Crohn's disease, Tysabri blocks the interaction of a particular protein called α4β7 integrin with the endothelial receptor MAdCAM-1. MAdCAM-1 is mainly expressed in gut tissue, and expression of MAdCAM-1 is increased at active sites of inflammation in people with Crohn's disease, and may significantly increase the recruitment of leukocytes to the mucosa.
Tysabri (natalizumab) may be used to treat adults with multiple sclerosis or Crohn's disease and is given once every four weeks by a registered infusion center or pharmacy that is enrolled in the Touch Prescribing program. A headache, fatigue, joint pain, and infections are the most common side effects reported although rarely, it may cause more serious side effects such as liver failure, severe herpes infections, or PML. It may not be suitable for people who already have a weakened immune system.
References
- Tysabri injection (natalizumab). Updated 06/2020. Biogen Inc. https://www.drugs.com/pro/tysabri.html#s-34090-1
- TYSABRI clinical trial results 2021. https://www.tysabri.com/en_us/home/about/long-term-study.html
- Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007;3(2):259-268. doi:10.2147/tcrm.2007.3.2.259
Read next
Related medical questions
- Does Tysabri cause cancer?
- How long does a Tysabri infusion take?
- What biosimilars have been approved in the United States?
- How to prevent hair loss from Tysabri (natalizumab)?
- How long can you live with multiple sclerosis?
- What are the early warning signs of Multiple Sclerosis?
- How do you test for multiple sclerosis?
- What are the early signs of multiple sclerosis?
- Prednisone: What are 12 Things You Should Know?
- Prednisone vs Prednisolone - What's the difference?
- What are the new drugs used for multiple sclerosis (MS)?
- Is Kesimpta better than Ocrevus?
- How much does an Ocrevus infusion cost?
- What are 8 key Kesimpta side effects to watch out for?
- Who is the actress in the Kesimpta commercial?
- Is Tecfidera an immunosuppressant?
- How do Vumerity and Tecfidera compare for multiple sclerosis (MS)?
- How long does it take Ocrevus to work?
- Can I stop taking Tecfidera? What happens if I do?
- Is Ocrevus a form of chemotherapy?
- How long does an Ocrevus infusion take?
- What causes flushing with Tecfidera?
- Can you drink alcohol while taking Tecfidera?
- Where and how should Copaxone be injected?
- How does Ocrevus work for MS?
- Ocrevus vs Aubagio: How do they compare for MS?
- How effective is Mavenclad for MS?
- Gilenya vs Tecfidera. How do they compare?
- How long can you take Tecfidera?
- What happens when you stop taking Gilenya?
Drug information
Related support groups
- Tysabri (9 questions, 71 members)
- Natalizumab (6 questions, 8 members)
- Multiple Sclerosis (90 questions, 549 members)
- Crohn's Disease - Maintenance (22 questions, 97 members)